DDX17 Nucleocytoplasmic Shuttling Promotes Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells via Activation of Β-Catenin

Cancer Letters - Ireland
doi 10.1016/j.canlet.2017.02.029
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines

Journal of Cancer
Oncology
2020English

Mechanism Research of miR‐34a Regulates Axl in Non‐small‐cell Lung Cancer With Gefitinib‐acquired Resistance

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

CtBP2 Promotes Proliferation and Reduces Drug Sensitivity in Non-Small Cell Lung Cancer via the WNT/Β-Catenin Pathway

Neoplasma
Cancer Research
2018English

P2.13-34 Long Intergenic Non-Coding RNA 00665 Induces Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Circ-Sox4 Promotes Non-Small Cell Lung Cancer Progression by Activating the WNT/Β-Catenin Pathway

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2020English

Inhibition of SREBP Increases Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2016English

Overexpression of OCT4 Is Associated With Gefitinib Resistance in Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Atorvastatin Overcomes Gefitinib Resistance in KRAS Mutant Human Non-Small Cell Lung Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy